Compound testing in over
400 genetically characterized 
patient-derived xenograft cultures

Patient-derived xenograft (PDX) models are genetically annotated human tumors commonly used for in vivo compound testing.

OcellO offers compound testing services using ex vivo cultured tumoroids derived from PDX tumor.  Tumoroids  are embedded in physiologically-relevant extracellular matrix protein-rich hydrogel which enables  in vivo characteristics such as histology and drug responsiveness to be maintained. Over 100 tumoroids are grown in each well of a 384-well plate format, for robust high throughput testing. This  approach  allows detection of active, selective and cytotoxic compounds,  antibodies,  ADCs  and drug combinations  in relevant models  that can be followed up in the same tumor models in vivo  with our partners  at Charles River Labs.

Choose from several hundred well-characterized
tumor PDX models from the Charles River collection, including:

Functional endpoints: inhibition of tumor growth

Select a panels of tumor models with the
appropriate mutation profiles or target expression.
Scalable format suitable for compound screening,
lead profiling or testing drug combinations.

Key advantages

  • Well characterized human tumor tissue
  • Scalable 384 well platform – test
    multiple compounds and/or multiple
    tumor models
  • Direct translation from in vitro to in vivo
    or from in vivo to in vitro.
  • Rapid turnaround and small amounts
    of compound required compared to
    in vivo

Functional endpoints: HER2  targeting and inhibition by  ADCs

HER2 overexpressing gastric tumor cells (GXA-3067) were grown into tumoroids in 3D and exposed to  increasing doses of Trastuzumab, Kadcyla (T-DM1)  and a novel HER2 antibody drug conjugate (ADC).  Tumoroids can be fixed in the 384 well plate and stained (e.g. here with anti HER2 antibody) or embedded in paraffin for histology and immunostaining.

Assay Principle

Short term ex vivo 3D culture expansion of patient-derived tumor material in a 3D environment and subsequent exposure to cancer therapeutics enables clinically-relevant functional in vitro testing of pre-clinical compounds.

Using a high throughput 384 well plate format, over 100 tumoroids per well can be exposed to multiple drug treatments, dose ranges and drug combinations in parallel. Tumoroids are fixed and stained with cellular markers. 3D image stack acquisition is followed by high content multi-parametric analysis using the OMinerTM platform to profile drug responses and quantify tumor spheroid volume, apoptosis and tumor invasion. This compound testing platform allows drug testing in well characterized PDX tumor material with the option of in vivo follow-up in the same PDX model from which the tumor cells were derived.